MEA Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143403
- Pages: 225
-
Format:
Short Description
Middle East and Africa Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Definition:
Leber congenital amaurosis (LCA) is a part of the spectrum of early-onset retinal dystrophy (EORD). It usually presents in the first few years of life, most often before the age of 1 year. This condition is the most common cause of inherited blindness in childhood. Symptoms include vision loss, roving eye movements, deep-set eyes, developmental delay, epilepsy, and motor skill impairment.
Market Segmentation:
Middle East and Africa leber congenital amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel.
On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others.
On the basis of type, the leber congenital amaurosis market is segmented into diagnosis and therapy.
On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others.
Market Players
The key market players for Middle East and Africa leber congenital amaurosis market are listed below:
Invitae Corporation
Spark Therapeutics, Inc.
LKC TECHNOLOGIES, INC
CENTOGENE N.V.
Optos, Metrovision
Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics)
CD Genomics
ProQR Therapeutics
OCUGEN, INC.
MeiraGTx Limited
Coave Therapeutics
IVERIC bio, Inc.
Atsena Therapeutics
Editas Medicine
Eluminex Biosciences
Okuvision
Astellas Pharma Inc.
Allergan (A Subsidiary of Abbvie Inc.)
AGTC
Gyroscope Therapeutics Limited
SparingVision
Kubota Pharmaceutical Holdings Co. Ltd.
REGENXBIO Inc
TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET 44
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 CURRENCY AND PRICING 51
2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
2.6 MULTIVARIATE MODELLING 55
2.7 DISEASE TYPE LIFELINE CURVE 55
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.9 DBMR MARKET POSITION GRID 57
2.10 MARKET END USER COVERAGE GRID 58
2.11 VENDOR SHARE ANALYSIS 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 64
4.1 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA LEBER CONGENTIAL AMAUROSIS MARKET 66
4.2 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 68
4.3 PESTEL ANALYSIS 71
4.4 PORTERS FIVE FORCES 72
5 EPIDEMIOLOGY 73
6 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 74
6.1 DRIVERS 76
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 76
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 79
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 85
6.2 RESTRAINTS 86
6.2.1 LACK OF QUALIFIED PROFESSIONALS 86
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 87
6.3 OPPORTUNITIES 88
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 88
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 88
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 89
6.4 CHALLENGES 90
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 90
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 90
7 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 91
7.1 OVERVIEW 92
7.2 INFANTILE TYPE 95
7.3 JUVENILE TYPE 95
7.4 OTHERS 96
8 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 97
8.1 OVERVIEW 98
8.2 THERAPY 101
8.2.1 GENE THERAPY 102
8.2.1.1 LUXTURNA 102
8.2.2 RETINAL PROSTHETIC 102
8.2.3 NEUROPROTECTIVE AGENTS 102
8.2.3.1 VITAMIN A PALMITATE 103
8.2.3.2 DOCOSAHEXAENOIC ACID 103
8.2.3.3 LUTEIN 103
8.2.3.4 OTHERS 103
8.2.4 OTHERS 103
8.3 DIAGNOSIS 104
8.3.1 CLINICAL DIAGNOSIS 105
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 105
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 106
8.3.1.1.2 DARK ADAPTOMETRY (DA) 106
8.3.1.2 RETINAL IMAGING 106
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 106
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 107
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 107
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 107
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 107
8.3.1.3 VISUAL FIELD TEST 107
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 107
8.3.1.3.2 MANUAL FIELD TEST 107
8.3.1.4 CLINICAL EYE EXAMINATION 108
8.3.1.4.1 SLIT LAMP 108
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 108
8.3.1.4.3 REFRACTION TEST 108
8.3.1.4.4 DILATION EXAM 108
8.3.1.5 OTHERS 108
8.3.2 GENETIC DIAGNOSIS 109
9 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 110
9.1 OVERVIEW 111
9.2 HOSPITALS 114
9.3 SPECIALITY CLINICS 115
9.4 AMBULATORY SURGICAL CENTERS 116
9.5 HOME HEALTHCARE 117
9.6 OTHERS 118
10 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 119
10.1 OVERVIEW 120
10.2 RETAIL SALES 123
10.2.1.1 HOSPITAL PHARMACIES 124
10.2.1.2 RETAIL PHARMACIES 124
10.2.1.3 OTHERS 124
10.3 DIRECT TENDER 124
11 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 125
11.1 MIDDLE EAST AND AFRICA 126
11.1.1 SOUTH AFRICA 133
11.1.2 SAUDI ARABIA 137
11.1.3 U.A.E 141
11.1.4 ISRAEL 145
11.1.5 EGYPT 149
11.1.6 KUWAIT 153
11.1.7 REST OF MIDDLE EAST AND AFRICA 157
12 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 158
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 158
13 SWOT ANALYSIS 159
14 COMPANY PROFILE 160
14.1 SPARK THERAPEUTICS, INC 160
14.1.1 COMPANY SNAPSHOT 160
14.1.2 COMPANY SHARE ANALYSIS 160
14.1.3 PRODUCT PORTFOLIO 161
14.1.4 RECENT DEVELOPMENT 161
14.1.4.1 EU AUTHORIZATION 161
14.2 OPTOS 162
14.2.1 COMPANY SNAPSHOT 162
14.2.2 COMPANY SHARE ANALYSIS 162
14.2.3 PRODUCT PORTFOLIO 163
14.2.4 RECENT DEVELOPMENT 163
14.2.4.1 PRODUCT APPROVAL 163
14.3 CD GENOMICS 164
14.3.1 COMPANY SNAPSHOT 164
14.3.2 COMPANY SHARE ANALYSIS 164
14.3.3 PRODUCT PORTFOLIO 165
14.3.4 RECENT DEVELOPMENT 165
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 166
14.4.1 COMPANY SNAPSHOT 166
14.4.2 REVENUE ANALYSIS 166
14.4.3 COMPANY SHARE ANALYSIS 167
14.4.4 PRODUCT PORTFOLIO 167
14.4.5 RECENT DEVELOPMENTS 167
14.4.5.1 COLLABORATION 167
14.5 LKC TECHNOLOGIES, INC 168
14.5.1 COMPANY SNAPSHOT 168
14.5.2 COMPANY SHARE ANALYSIS 168
14.5.3 PRODUCT PORTFOLIO 169
14.5.4 RECENT DEVELOPMENT 169
14.5.4.1 PRODUCT APPROVAL 169
14.5.5 PRODUCT APPROVAL 169
14.6 AGTC 170
14.6.1 COMPANY SNAPSHOT 170
14.6.2 REVENUE ANALYSIS 170
14.6.3 PRODUCT PORTFOLIO 171
14.6.4 RECENT DEVELOPMENTS 171
14.6.4.1 AGREEMENT 171
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 172
14.7.1 COMPANY SNAPSHOT 172
14.7.2 REVENUE ANALYSIS 172
14.7.3 PRODUCT PORTFOLIO 173
14.7.4 RECENT DEVELOPMENTS 173
14.8 ASTELLAS PHARMA INC. 174
14.8.1 COMPANY SNAPSHOT 174
14.8.2 REVENUE ANALYSIS 174
14.8.3 PRODUCT PORTFOLIO 175
14.8.4 RECENT DEVELOPMENT 175
14.9 ATSENA THERAPEUTICS 176
14.9.1 COMPANY SNAPSHOT 176
14.9.2 PRODUCT PORTFOLIO 176
14.9.3 RECENT DEVELOPMENT 176
14.10 CENTOGENE N.V. 177
14.10.1 COMPANY SNAPSHOT 177
14.10.2 REVENUE ANALYSIS 177
14.10.3 PRODUCT PORTFOLIO 178
14.10.4 RECENT DEVELOPMENT 178
14.10.4.1 PRODUCT LAUNCH 178
14.11 COAVE THERAPEUTICS 179
14.11.1 COMPANY SNAPSHOT 179
14.11.2 PRODUCT PORTFOLIO 179
14.11.3 RECENT DEVELOPMENT 179
14.12 EDITAS MEDICINE 180
14.12.1 COMPANY SNAPSHOT 180
14.12.2 REVENUE ANALYSIS 180
14.12.3 PRODUCT PORTFOLIO 181
14.12.4 RECENT DEVELOPMENTS 181
14.12.4.1 DATA & TRAIL DATA PRESENTATION 181
14.13 ELUMINEX BIOSCIENCES 182
14.13.1 COMPANY SNAPSHOT 182
14.13.2 PRODUCT PORTFOLIO 182
14.13.3 RECENT DEVELOPMENT 182
14.14 GYROSCOPE THERAPEUTICS LIMITED 183
14.14.1 COMPANY SNAPSHOT 183
14.14.2 PRODUCT PORTFOLIO 183
14.14.3 RECENT DEVELOPMENTS 183
14.15 INVITAE CORPORATION 185
14.15.1 COMPANY SNAPSHOT 185
14.15.2 REVENUE ANALYSIS 185
14.15.3 PRODUCT PORTFOLIO 186
14.15.4 RECENT DEVELOPMENTS 186
14.15.4.1 NEW FACILITY 186
14.15.4.2 EXPANSION 186
14.16 IVERIC BIO. 187
14.16.1 COMPANY SNAPSHOT 187
14.16.2 PRODUCT PORTFOLIO 187
14.16.3 RECENT DEVELOPMENT 187
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 188
14.17.1 COMPANY SNAPSHOT 188
14.17.2 REVENUE ANALYSIS 188
14.17.3 PRODUCT PORTFOLIO 189
14.17.4 RECENT DEVELOPMENTS 189
14.18 MEIRAGTX LIMITED 190
14.18.1 COMPANY SNAPSHOT 190
14.18.2 PRODUCT PORTFOLIO 190
14.18.3 RECENT DEVELOPMENT 190
14.19 METROVISION 192
14.19.1 COMPANY SNAPSHOT 192
14.19.2 PRODUCT PORTFOLIO 192
14.19.3 RECENT DEVELOPMENT 192
14.19.3.1 FDA CLEARANCE APPROVAL 192
14.20 OCUGEN INC. 193
14.20.1 COMPANY SNAPSHOT 193
14.20.2 PRODUCT PORTFOLIO 193
14.20.3 RECENT DEVELOPMENT 193
14.21 OKUVISION 194
14.21.1 COMPANY SNAPSHOT 194
14.21.2 PRODUCT PORTFOLIO 194
14.21.3 RECENT DEVELOPMENTS 194
14.21.3.1 APPROVAL 194
14.22 PROQR THERAPEUTICS 195
14.22.1 COMPANY SNAPSHOT 195
14.22.2 PRODUCT PORTFOLIO 195
14.22.3 RECENT DEVELOPMENTS 195
14.23 REGENXBIO INC. 196
14.23.1 COMPANY SNAPSHOT 196
14.23.2 REVENUE ANALYSIS 196
14.23.3 PRODUCT PORTFOLIO 197
14.23.4 RECENT DEVELOPMENTS 197
14.24 SPARINGVISION 198
14.24.1 COMPANY SNAPSHOT 198
14.24.2 PRODUCT PORTFOLIO 198
14.24.3 RECENT DEVELOPMENTS 198
15 QUESTIONNAIRE 199
16 RELATED REPORTS 202
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
